Bioresponsive nanocarriers for controlled and targeted delivery to efficiently treat Inflammatory Bowel Disease (IBD)

用于受控和靶向递送的生物响应性纳米载体可有效治疗炎症性肠病 (IBD)

• 批准号: nhmrc : 1071796
• 金额: $ 21.1万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Early Career Fellowships
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/bioresponsive-nanocarriers-controlled-disease-ibd/455474
• 关键词: Bioresponsive; nanocarriers; controlled; targeted; delivery

Despite considerable progress in treatment of Inflammatory Bowel Diseases, current treatments suffer from many disadvantages such as side effects, lack of efficacy in many patients, and development of drug dependence. Using state of art nanotechnology, novel nanoparticles will be developed to enhance the delivery to the intestine and efficacy of Budesonide (an anti-inflammatory steroid). This research promises to find safer and more effective ways to treat these diseases.

尽管炎症性肠病的治疗取得了相当大的进展，但目前的治疗方法存在许多缺点，如副作用，许多患者缺乏疗效，以及药物依赖性的发展。利用最先进的纳米技术，新的纳米粒子将被开发出来，以增强布地奈德（一种抗炎类固醇）的肠内递送和功效。这项研究有望找到更安全、更有效的方法来治疗这些疾病。